• Explore /
  • Poster
  • / A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).

A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).

Abstract Poster

Authors

null

Victoria K Woodcock

Department of Oncology, University of Oxford, Oxford, United Kingdom

Victoria K Woodcock , Karin Purshouse , Chrissie Butcher , Caroline Haddon , Gillian Verrall , Leena Elhussein , Mariolina Salio , Mark R. Middleton , Vincenzo Cerundolo , Jeremy Crew , Andrew Protheroe

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT03167151

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 406)

DOI

10.1200/JCO.2019.37.7_suppl.406

Abstract #

406

Poster Bd #

G19

Abstract Disclosures

Similar Posters

First Author: Roger Li

First Author: Hizra Farrukh

First Author: Ashish M. Kamat

Poster

2022 ASCO Genitourinary Cancers Symposium

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

First Author: Shruthi Naik